Detected ·
General Biotechnologies
$7.4M—
General Biotechnologies raised $7.4M to develop oral GLP-1 therapeutics using CRISPR-engineered volcanic microbes, targeting $3–$5 per patient per day, with three peptide products planned for a 2027 launch. The round was led alongside Cartography Capital and Ritual Capital.
- Website
- www.general.bio
- linkedin.com/company/general-bio
- Amount
- $7 400 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-07-21 12:05:14 UTC
- Signal ID
- 040914ff-0f00-4c29-82e9-dc6eb761043a
As the API returns it
{
"id": "040914ff-0f00-4c29-82e9-dc6eb761043a",
"created_at": "2026-07-21T12:05:14.935756Z",
"company_name": "General Biotechnologies",
"company_website_url": "www.general.bio",
"company_linkedin_url": "https://www.linkedin.com/company/general-bio",
"event_type": "funding",
"funding_amount": 7400000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*General Biotechnologies raised $7.4M to develop oral GLP-1 therapeutics using CRISPR-engineered volcanic microbes, targeting $3–$5 per patient per day, with three peptide products planned for a 2027 launch. The round was led alongside Cartography Capital and Ritual Capital.*"
}